Enliven Therapeutics, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Enliven is a clinical-stage oncology biotechnology company with no approved products and no revenue. The February 23, 2023 merger with Imara was accounted for as a reverse recapitalization, with Former Enliven as the accounting acquirer; accordingly, historical operating results are primarily those of Former Enliven.
Financial results and position
| Metric | Q1 2023 | Q1 2022 / comparator |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $11.9 million | $7.1 million |
| General and administrative expense | $4.5 million | $1.6 million |
| Total operating expenses | $16.4 million | $8.7 million |
| Interest income | $1.7 million | $9,000 |
| Net loss | $14.7 million | $8.7 million |
| Basic and diluted loss per share | $0.80 | $3.01 |
| Net cash used in operating activities | $20.8 million | $10.4 million |
At March 31, 2023, cash and cash equivalents were $292.1 million; total assets were $302.9 million, current liabilities $10.9 million, total liabilities $11.5 million, and accumulated deficit $97.6 million. The company reported no debt. Cash and cash equivalents consisted primarily of U.S. Treasury-backed money market funds. No meaningful revenue or operating margin is available to assess.
Cash flow also included $31,000 of investing outflow and $237.4 million of financing inflow, principally $162.9 million net proceeds from the pre-merger financing and $81.8 million cash acquired in the reverse recapitalization, partially offset by transaction costs. Ending cash, cash equivalents and restricted cash totaled $292.2 million.
Changes, transactions and unusual items
- R&D expense increased $4.8 million year over year, mainly from clinical trial and external development costs, as well as increased personnel and other internal costs.
- G&A expense increased $2.9 million, including $1.3 million of stock-based compensation from accelerated option vesting at the merger, higher professional services, and other costs.
- Interest income rose substantially due to higher cash balances and interest rates. Net loss increased despite that income, reflecting higher operating expenses.
- The February merger converted Former Enliven preferred stock into common stock. The pre-merger financing generated $164.5 million gross proceeds; $9.0 million of reverse-recapitalization transaction costs reduced equity.
- Per-share loss comparisons are affected by the merger, reverse stock split and substantial change in weighted-average shares; the filing’s comparative results reflect reverse-recapitalization accounting.
Outlook, risks and contingencies
Management expects operating losses and negative operating cash flows to continue as development advances. The filing says March 31 cash is expected to fund planned operating expenses and capital requirements for at least 12 months from issuance of the financial statements; elsewhere, the risk factors state that cash at merger closing, including financing proceeds, is expected to fund operations into early 2026. These are management estimates, not guarantees, and depend on the operating plan and assumptions. The company anticipates needing substantial additional capital over time.
- ELVN-001 was being evaluated in a Phase 1 trial for chronic myeloid leukemia; ELVN-002’s Phase 1 trial began in early 2023. No specific trial milestones or financial guidance are provided in the filing text.
- Key risks include clinical failure or delay, patient enrollment, regulatory uncertainty, competition, intellectual-property protection, and dependence on third-party CROs and manufacturers. The company has no manufacturing facilities and reports single-source supply exposure for API and drug product. Pharmaron had experienced COVID-related delays; its China location also raises potential supply, policy and currency risks.
- Macroeconomic and geopolitical uncertainty, including banking-sector instability, inflation, credit conditions and the Russia-Ukraine conflict, could affect operations or future financing. The company reported no material business disruption or asset impairment to date. Cash balances exceeded federally insured limits.
- A merger-related shareholder disclosure lawsuit was voluntarily dismissed in January 2023 after supplemental disclosures; the company agreed to an immaterial mootness fee. The company reported no current material litigation.
- Operating lease payments totaled $588,000 through 2024. Vendor agreements may include termination or purchase obligations not separately quantified. No off-balance-sheet arrangements were reported.
- Management concluded disclosure controls were effective at a reasonable assurance level as of March 31, 2023.
Important facts for investors to verify
- Cash-burn assumptions and the basis for the stated runway, including the “at least 12 months” estimate and the separate “into early 2026” statement.
- Clinical progress, enrollment, safety and upcoming milestones for ELVN-001 and ELVN-002; the filing provides no detailed trial results or milestone dates.
- How R&D spending and operating cash use evolve as trials advance, and whether additional financing will be required sooner than expected.
- Third-party manufacturing and CRO capacity, single-source supply dependencies, and potential effects of China-related disruptions.
- Post-merger share count, equity-plan dilution, and the potential market impact when merger-related lock-ups expire.